January 14, 2026: NCHR comment to CMS explains TAVR doesn’t provide meaningful benefits to asymptomatic patients because patients in the EARLY TAVR study did not live longer or avoid disabling strokes and it did not evaluate typical Medicare patients or typical treatment or safeguards available to TAVR patients.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Letter to Montgomery County About the Dangers of Artificial Turf
December 8, 2025: NCHR letter from constituent Diana Zuckerman to Montgomery County Maryland Executive and Council explains the many ways that artificial turf is dangerous for our children and our community. Well-maintained natural grass is better, less expensive, and ADA-compliant.
Read More »Testimony of Dr. Diana Zuckerman at the FDA Circulatory System Devices Advisory Panel Meeting on V-Wave Ventura Shunt
December 3, 2025: Diana Zuckerman urges FDA Advisory Devices Panel to require more research on Ventura shunt to make sure it is more effective than sham control placebo group. She points out the well-designed study did not meet primary endpoint to improve cardiac results for patients.
Read More »Testimony of Dr. Diana Zuckerman at the FDA Advisory Committee On Digital Health
NCHR’s Dr. Diana Zuckerman testified at the FDA Advisory Committee meeting on Digital mental health products, expressing concerns about FDA’s failure to regulate the Chatbots and other digital products being marketed as “licensed therapists” and used as psychotherapists in ways that can be extremely harmful. She urged better research but acknowledged difficulty of studying devices that are updated frequently
Read More »NCHR Comments on Development of Non-Opioid Analgesics for Chronic Pain
National Center for Health Research submitted a written public comment to the FDA docket that advised the agency on the kinds of research needed to ensure that non-opioid pain medications are safe and effective for chronic pain and patients can make informed choices. We point out that it would be unethical to conduct studies that compare these products to opioids in clinical trials.
Read More »